keyword
MENU ▼
Read by QxMD icon Read
search

Ralph defronzo

keyword
https://www.readbyqxmd.com/read/29672742/older-subjects-with-%C3%AE-cell-dysfunction-have-an-accentuated-incretin-release
#1
José de Jesús Garduno-Garcia, Amalia Gastaldelli, Ralph A DeFronzo, Raweewan Lertwattanarak, Jens J Holst, Nicolas Musi
Objective: Insulin secretion declines with age and this contributes to the increased risk of developing impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM) in older subjects. Insulin secretion is regulated by the incretin hormones glucagon-like peptide (GLP) 1 and glucose-dependent insulinotropic peptide (GIP). Here we tested the hypotheses that incretin release is reduced in older subjects, and that this decline is associated with β-cell dysfunction. Research Design: 40 young (25±3 y) and 53 older (74±7 y) lean non-diabetic subjects underwent a 2 h oral glucose tolerance test (OGTT)...
April 16, 2018: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29602791/endogenous-glucose-production-and-hormonal-changes-in-response-to-canagliflozin-and-liraglutide-combination-therapy
#2
Robert Martinez, Hussein Al-Jobori, Ali M Ali, John Adams, Muhammad Abdul-Ghani, Curtis Triplitt, Ralph DeFronzo, Eugenio Cersosimo
The decrement in plasma glucose concentration with SGLT2i is blunted by a rise in endogenous glucose production (EGP). We investigated the ability of incretin treatment to offset the EGP increase. T2DM (n=36) subjects were randomized to: (i) CANAgliflozin (ii) LIRAglutide (iii) CANA/LIRA. EGP was measured with 3-3 H-glucose with/without drug for 360 minutes. In the pre-treatment studies EGP (mg/kg•min) was comparable and decreased (2.2±0.1 to 1.7±0.2) during 300-360 minute period (p<0.01). The decrement in EGP was attenuated with CANA (2...
March 30, 2018: Diabetes
https://www.readbyqxmd.com/read/29509433/reduced-skeletal-muscle-phosphocreatine-concentration-in-type-2-diabetic-patients-a-quantitative-image-based-phosphorus-31-mr-spectroscopy-study
#3
Erika M Ripley, Geoffrey D Clarke, Vala Hamidi, Robert A Martinez, Floyd D Settles, Carolina Solis, Shengwen Deng, Muhammad Abdul-Ghani, Devjit Tripathy, Ralph A DeFronzo
Mitochondrial dysfunction has been described in insulin resistant (IR) states including type 2 diabetes mellitus (T2DM). Previous studies using 31 P-MRS in T2DM reported results as relative concentrations of metabolite ratios, which could obscure changes in phosphocreatine [PCr] and [ATP] and attenuate differences between T2DM and NGT individuals. We used a novel image-guided 31 P-MRS method to quantitate phosphorus metabolites in vastus lateralis (VL) muscle in 11 T2DM and 14 NGT subjects. Subjects received OGTT, euglycemic insulin clamp, 31 P-MRS study to measure absolute concentrations (mM) of [PCr], inorganic phosphate [Pi], and [ATP], and VL muscle biopsy to evaluate mitochondrial density...
March 6, 2018: American Journal of Physiology. Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29460292/genetic-and-environmental-physical-fitness-and-sedentary-activity-interaction-effects-on-cardiometabolic-risk-factors-in-mexican-american-children-and-adolescents
#4
Rector Arya, Vidya S Farook, Sharon P Fowler, Sobha Puppala, Geetha Chittoor, Roy G Resendez, Srinivas Mummidi, Jairam Vanamala, Laura Almasy, Joanne E Curran, Anthony G Comuzzie, Donna M Lehman, Christopher P Jenkinson, Jane L Lynch, Ralph A DeFronzo, John Blangero, Daniel E Hale, Ravindranath Duggirala, Vincent P Diego
Knowledge on genetic and environmental (G × E) interaction effects on cardiometabolic risk factors (CMRFs) in children is limited.  The purpose of this study was to examine the impact of G × E interaction effects on CMRFs in Mexican American (MA) children (n = 617, ages 6-17 years). The environments examined were sedentary activity (SA), assessed by recalls from "yesterday" (SAy) and "usually" (SAu) and physical fitness (PF) assessed by Harvard PF scores (HPFS). CMRF data included body mass index (BMI), waist circumference (WC), fat mass (FM), fasting insulin (FI), homeostasis model of assessment-insulin resistance (HOMA-IR), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), systolic (SBP) and diastolic (DBP) blood pressure, and number of metabolic syndrome components (MSC)...
February 20, 2018: Genetic Epidemiology
https://www.readbyqxmd.com/read/29368965/consensus-statement-by-the-american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-on-the-comprehensive-type-2-diabetes-management-algorithm-2018-executive-summary
#5
Alan J Garber, Martin J Abrahamson, Joshua I Barzilay, Lawrence Blonde, Zachary T Bloomgarden, Michael A Bush, Samuel Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Vivian A Fonseca, Jeffrey R Garber, W Timothy Garvey, George Grunberger, Yehuda Handelsman, Irl B Hirsch, Paul S Jellinger, Janet B McGill, Jeffrey I Mechanick, Paul D Rosenblit, Guillermo E Umpierrez
A1C = hemoglobin A1C; AACE = American Association of Clinical Endocrinologists; ACCORD = Action to Control Cardiovascular Risk in Diabetes; ACCORD BP = Action to Control Cardiovascular Risk in Diabetes Blood Pressure; ACEI = angiotensin-converting enzyme inhibitor; ADVANCE = Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation; AGI = alpha-glucosidase inhibitor; apo B = apolipoprotein B; ASCVD = atherosclerotic cardiovascular disease; BAS = bile acid sequestrant; BCR-QR = bromocriptine quick release; BMI = body mass index; BP = blood pressure; CCB = calcium channel blocker; CHD = coronary heart disease; CKD = chronic kidney disease; CVD = cardiovascular disease; DASH = Dietary Approaches to Stop Hypertension; DPP4 = dipeptidyl peptidase 4; eGFR = estimated glomerular filtration rate; ER = extended release; FDA = Food and Drug Administration; GLP1 = glucagon-like peptide 1; HDL-C = high-density lipoprotein cholesterol; IMPROVE-IT = Improved Reduction of Outcomes: Vytorin Efficacy International Trial; LDL-C = low-density lipoprotein cholesterol; LDL-P = low-density lipoprotein particle; Look AHEAD = Look Action for Health in Diabetes; NPH = neutral protamine Hagedorn; OSA = obstructive sleep apnea; RCT = randomized controlled trial; SU = sulfonylurea; SGLT2 = sodium glucose cotransporter-2; SMBG = self-monitoring of blood glucose; T2D = type 2 diabetes; TZD = thiazolidinedione; VADT = Veterans Affairs Diabetes Trial...
January 2018: Endocrine Practice
https://www.readbyqxmd.com/read/29360107/erratum-sequence-data-and-association-statistics-from-12-940-type-2-diabetes-cases-and-controls
#6
Jason Flannick, Christian Fuchsberger, Anubha Mahajan, Tanya M Teslovich, Vineeta Agarwala, Kyle J Gaulton, Lizz Caulkins, Ryan Koesterer, Clement Ma, Loukas Moutsianas, Davis J McCarthy, Manuel A Rivas, John R B Perry, Xueling Sim, Thomas W Blackwell, Neil R Robertson, N William Rayner, Pablo Cingolani, Adam E Locke, Juan Fernandez Tajes, Heather M Highland, Josee Dupuis, Peter S Chines, Cecilia M Lindgren, Christopher Hartl, Anne U Jackson, Han Chen, Jeroen R Huyghe, Martijn van de Bunt, Richard D Pearson, Ashish Kumar, Martina Müller-Nurasyid, Niels Grarup, Heather M Stringham, Eric R Gamazon, Jaehoon Lee, Yuhui Chen, Robert A Scott, Jennifer E Below, Peng Chen, Jinyan Huang, Min Jin Go, Michael L Stitzel, Dorota Pasko, Stephen C J Parker, Tibor V Varga, Todd Green, Nicola L Beer, Aaron G Day-Williams, Teresa Ferreira, Tasha Fingerlin, Momoko Horikoshi, Cheng Hu, Iksoo Huh, Mohammad Kamran Ikram, Bong-Jo Kim, Yongkang Kim, Young Jin Kim, Min-Seok Kwon, Juyoung Lee, Selyeong Lee, Keng-Han Lin, Taylor J Maxwell, Yoshihiko Nagai, Xu Wang, Ryan P Welch, Joon Yoon, Weihua Zhang, Nir Barzilai, Benjamin F Voight, Bok-Ghee Han, Christopher P Jenkinson, Teemu Kuulasmaa, Johanna Kuusisto, Alisa Manning, Maggie C Y Ng, Nicholette D Palmer, Beverley Balkau, Alena Stančáková, Hanna E Abboud, Heiner Boeing, Vilmantas Giedraitis, Dorairaj Prabhakaran, Omri Gottesman, James Scott, Jason Carey, Phoenix Kwan, George Grant, Joshua D Smith, Benjamin M Neale, Shaun Purcell, Adam S Butterworth, Joanna M M Howson, Heung Man Lee, Yingchang Lu, Soo-Heon Kwak, Wei Zhao, John Danesh, Vincent K L Lam, Kyong Soo Park, Danish Saleheen, Wing Yee So, Claudia H T Tam, Uzma Afzal, David Aguilar, Rector Arya, Tin Aung, Edmund Chan, Carmen Navarro, Ching-Yu Cheng, Domenico Palli, Adolfo Correa, Joanne E Curran, Dennis Rybin, Vidya S Farook, Sharon P Fowler, Barry I Freedman, Michael Griswold, Daniel Esten Hale, Pamela J Hicks, Chiea-Chuen Khor, Satish Kumar, Benjamin Lehne, Dorothée Thuillier, Wei Yen Lim, Jianjun Liu, Marie Loh, Solomon K Musani, Sobha Puppala, William R Scott, Loïc Yengo, Sian-Tsung Tan, Herman A Taylor, Farook Thameem, Gregory Wilson, Tien Yin Wong, Pål Rasmus Njølstad, Jonathan C Levy, Massimo Mangino, Lori L Bonnycastle, Thomas Schwarzmayr, João Fadista, Gabriela L Surdulescu, Christian Herder, Christopher J Groves, Thomas Wieland, Jette Bork-Jensen, Ivan Brandslund, Cramer Christensen, Heikki A Koistinen, Alex S F Doney, Leena Kinnunen, Tõnu Esko, Andrew J Farmer, Liisa Hakaste, Dylan Hodgkiss, Jasmina Kravic, Valeri Lyssenko, Mette Hollensted, Marit E Jørgensen, Torben Jørgensen, Claes Ladenvall, Johanne Marie Justesen, Annemari Käräjämäki, Jennifer Kriebel, Wolfgang Rathmann, Lars Lannfelt, Torsten Lauritzen, Narisu Narisu, Allan Linneberg, Olle Melander, Lili Milani, Matt Neville, Marju Orho-Melander, Lu Qi, Qibin Qi, Michael Roden, Olov Rolandsson, Amy Swift, Anders H Rosengren, Kathleen Stirrups, Andrew R Wood, Evelin Mihailov, Christine Blancher, Mauricio O Carneiro, Jared Maguire, Ryan Poplin, Khalid Shakir, Timothy Fennell, Mark DePristo, Martin Hrabé de Angelis, Panos Deloukas, Anette P Gjesing, Goo Jun, Peter Nilsson, Jacquelyn Murphy, Robert Onofrio, Barbara Thorand, Torben Hansen, Christa Meisinger, Frank B Hu, Bo Isomaa, Fredrik Karpe, Liming Liang, Annette Peters, Cornelia Huth, Stephen P O'Rahilly, Colin N A Palmer, Oluf Pedersen, Rainer Rauramaa, Jaakko Tuomilehto, Veikko Salomaa, Richard M Watanabe, Ann-Christine Syvänen, Richard N Bergman, Dwaipayan Bharadwaj, Erwin P Bottinger, Yoon Shin Cho, Giriraj R Chandak, Juliana C N Chan, Kee Seng Chia, Mark J Daly, Shah B Ebrahim, Claudia Langenberg, Paul Elliott, Kathleen A Jablonski, Donna M Lehman, Weiping Jia, Ronald C W Ma, Toni I Pollin, Manjinder Sandhu, Nikhil Tandon, Philippe Froguel, Inês Barroso, Yik Ying Teo, Eleftheria Zeggini, Ruth J F Loos, Kerrin S Small, Janina S Ried, Ralph A DeFronzo, Harald Grallert, Benjamin Glaser, Andres Metspalu, Nicholas J Wareham, Mark Walker, Eric Banks, Christian Gieger, Erik Ingelsson, Hae Kyung Im, Thomas Illig, Paul W Franks, Gemma Buck, Joseph Trakalo, David Buck, Inga Prokopenko, Reedik Mägi, Lars Lind, Yossi Farjoun, Katharine R Owen, Anna L Gloyn, Konstantin Strauch, Tiinamaija Tuomi, Jaspal Singh Kooner, Jong-Young Lee, Taesung Park, Peter Donnelly, Andrew D Morris, Andrew T Hattersley, Donald W Bowden, Francis S Collins, Gil Atzmon, John C Chambers, Timothy D Spector, Markku Laakso, Tim M Strom, Graeme I Bell, John Blangero, Ravindranath Duggirala, E Shyong Tai, Gilean McVean, Craig L Hanis, James G Wilson, Mark Seielstad, Timothy M Frayling, James B Meigs, Nancy J Cox, Rob Sladek, Eric S Lander, Stacey Gabriel, Karen L Mohlke, Thomas Meitinger, Leif Groop, Goncalo Abecasis, Laura J Scott, Andrew P Morris, Hyun Min Kang, David Altshuler, Noël P Burtt, Jose C Florez, Michael Boehnke, Mark I McCarthy
This corrects the article DOI: 10.1038/sdata.2017.179.
January 23, 2018: Scientific Data
https://www.readbyqxmd.com/read/29342295/empagliflozin-treatment-is-associated-with-improved-beta-cell-function-in-t2dm
#7
Hussein Al Jobori, Giuseppe Daniele, John Adams, Eugenio Cersosimo, Carolina Solis-Herrera, Curtis Triplitt, Ralph A DeFronzo, Muhammad Abdul-Ghani
Objective: To examine whether lowering the plasma glucose concentration with empagliflozin (SGLT2 inhibitor) improves beta cell function in T2DM. Research Design and Methods: 15 T2DM patients received empagliflozin (25 mg/day) for 2 weeks, and beta cell function was measured with 9-step hyperglycemic clamp (each step = +40 mg/dl) before and 48 hours and 14 days after empagliflozin. Results: Empagliflozin caused 101±10 and 117±11 grams glucosuria on days 1 and 14 and produced 25±6 and 38±8 mg/dl reduction (p<0...
January 12, 2018: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29261667/increased-lipid-availability-for-three-days-reduces-whole-body-glucose-uptake-impairs-muscle-mitochondrial-function-and-initiates-opposing-effects-on-pgc-1%C3%AE-promoter-methylation-in-healthy-subjects
#8
Roy Eldor, Luke Norton, Marcel Fourcaudot, Cynthia Galindo, Ralph A DeFronzo, Muhammad Abdul-Ghani
AIMS: FFA and FFA metabolites cause insulin resistance and impair beta cell function. The goal of our research was to examine whether elevation of plasma FFA impairs mitochondrial function and alters PGC-1α promoter methylation. METHODS: In this uncontrolled, change from baseline study design, insulin sensitivity and glucose-stimulated insulin secretion were measured in 9 normal glucose tolerant subjects before and after 3 day lipid infusion to elevate plasma FFA concentration...
2017: PloS One
https://www.readbyqxmd.com/read/29227578/insulin-secretion-predicts-the-response-to-therapy-with-exenatide-plus-pioglitazone-but-not-to-basal-bolus-insulin-in-poorly-controlled-t2dm-patients-results-from-the-qatar-study
#9
Muhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, Rajvir Singh, Dalia Kamal, Ralph A DeFronzo, Amin Jayyousi
The present study aims to identify predictors for response to combination therapy with pioglitazone plus exenatide vs basal/bolus insulin therapy in T2DM patients who are poorly controlled with maximum/near-maximum doses of metformin plus a sulfonylurea. Participants in the Qatar study received a 75-g OGTT with measurement of plasma glucose, insulin and C-peptide concentration at baseline and were then randomized to receive either treatment with pioglitazone plus exenatide or basal/bolus insulin therapy for one year...
April 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29106450/a-novel-experimental-model-for-human-mixed-acinar-ductal-pancreatic-cancer
#10
Bruno Doiron, Ralph A DeFronzo
Pancreatic cancer has remained refractory to treatment. In large part, this results from the lack of an animal model that mimics pancreatic cancer in man. We describe a novel experimental model of pancreatic cancer that shares the genetic background, histologic features and natural history of human mixed acinar-ductal carcinoma. Adult wild-type mice received an injection into the pancreatic duct of lentivirus coding two molecules, KrasG12D mutation and shRNA p53, which recapitulate the mechanisms of pancreatic cancer in humans...
February 9, 2018: Carcinogenesis
https://www.readbyqxmd.com/read/29032755/insulin-resistance-the-link-between-t2dm-and-cvd-basic-mechanisms-and-clinical-implications
#11
Muhammad A Abdul-Ghani, Amin Jayyousi, Ralph A DeFronzo, Nidal Asaad, Jassim Al-Suwaidi
Insulin resistance (IR) is a cardinal feature of type 2 diabetes mellitus (T2DM). It also is associated with multiple metabolic abnormalities which are known cardiovascular disease (CVD) risk factors. Thus, IR not only contributes to the development of hyperglycemia in T2DM patients, but also to the elevated CVD risk. Improving insulin sensitivity is anticipated to both lower the plasma glucose concentration and decrease CVD risk in T2DM patients, independent of glucose control. We review the molecular mechanisms and metabolic consequences of IR in T2DM patients and discuss the importance of addressing IR in the management of T2DM...
October 10, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28887407/erratum-cardiovascular-disease-and-type-2-diabetes-has-the-dawn-of-a-new-era-arrived-diabetes-care-2017-40-813-820
#12
Muhammad Abdul-Ghani, Ralph A DeFronzo, Stefano Del Prato, Robert Chilton, Rajvir Singh, Robert E J Ryder
No abstract text is available yet for this article.
November 2017: Diabetes Care
https://www.readbyqxmd.com/read/28838971/a-loss-of-function-splice-acceptor-variant-in-igf2-is-protective-for-type-2-diabetes
#13
Josep M Mercader, Rachel G Liao, Avery D Bell, Zachary Dymek, Karol Estrada, Taru Tukiainen, Alicia Huerta-Chagoya, Hortensia Moreno-Macías, Kathleen A Jablonski, Robert L Hanson, Geoffrey A Walford, Ignasi Moran, Ling Chen, Vineeta Agarwala, María Luisa Ordoñez-Sánchez, Rosario Rodríguez-Guillen, Maribel Rodríguez-Torres, Yayoi Segura-Kato, Humberto García-Ortiz, Federico Centeno-Cruz, Francisco Barajas-Olmos, Lizz Caulkins, Sobha Puppala, Pierre Fontanillas, Amy L Williams, Sílvia Bonàs-Guarch, Chris Hartl, Stephan Ripke, Katherine Tooley, Jacqueline Lane, Carlos Zerrweck, Angélica Martínez-Hernández, Emilio J Córdova, Elvia Mendoza-Caamal, Cecilia Contreras-Cubas, María E González-Villalpando, Ivette Cruz-Bautista, Liliana Muñoz-Hernández, Donaji Gómez-Velasco, Ulises Alvirde, Brian E Henderson, Lynne R Wilkens, Loic Le Marchand, Olimpia Arellano-Campos, Laura Riba, Maegan Harden, Stacey Gabriel, Hanna E Abboud, Maria L Cortes, Cristina Revilla-Monsalve, Sergio Islas-Andrade, Xavier Soberon, Joanne E Curran, Christopher P Jenkinson, Ralph A DeFronzo, Donna M Lehman, Craig L Hanis, Graeme I Bell, Michael Boehnke, John Blangero, Ravindranath Duggirala, Richa Saxena, Daniel MacArthur, Jorge Ferrer, Steven A McCarroll, David Torrents, William C Knowler, Leslie J Baier, Noel Burtt, Clicerio González-Villalpando, Christopher A Haiman, Carlos A Aguilar-Salinas, Teresa Tusié-Luna, Jason Flannick, Suzanne B R Jacobs, Lorena Orozco, David Altshuler, Jose C Florez
Type 2 diabetes (T2D) affects more than 415 million people worldwide, and its costs to the health care system continue to rise. To identify common or rare genetic variation with potential therapeutic implications for T2D, we analyzed and replicated genome-wide protein coding variation in a total of 8,227 individuals with T2D and 12,966 individuals without T2D of Latino descent. We identified a novel genetic variant in the IGF2 gene associated with ∼20% reduced risk for T2D. This variant, which has an allele frequency of 17% in the Mexican population but is rare in Europe, prevents splicing between IGF2 exons 1 and 2...
November 2017: Diabetes
https://www.readbyqxmd.com/read/28733377/is-it-time-to-change-the-type-2-diabetes-treatment-paradigm-yes-glp-1-ras-should-replace-metformin-in-the-type-2-diabetes-algorithm
#14
Muhammad Abdul-Ghani, Ralph A DeFronzo
Most treatment guidelines, including those from the American Diabetes Association/European Association for the Study of Diabetes and the International Diabetes Federation, suggest metformin be used as the first-line therapy after diet and exercise. This recommendation is based on the considerable body of evidence that has accumulated over the last 30 years, but it is also supported on clinical grounds based on metformin's affordability and tolerability. As such, metformin is the most commonly used oral antihyperglycemic agent in the U...
August 2017: Diabetes Care
https://www.readbyqxmd.com/read/28637886/cardiovascular-disease-and-type-2-diabetes-has-the-dawn-of-a-new-era-arrived
#15
Muhammad Abdul-Ghani, Ralph A DeFronzo, Stefano Del Prato, Robert Chilton, Rajvir Singh, Robert E J Ryder
Hyperglycemia is the major risk factor for microvascular complications in patients with type 2 diabetes (T2D). However, cardiovascular disease (CVD) is the principal cause of death, and lowering HbA1c has only a modest effect on reducing CVD risk and mortality. The recently published LEADER and SUSTAIN-6 trials demonstrate that, in T2D patients with high CVD risk, the glucagon-like peptide 1 receptor agonists liraglutide and semaglutide reduce the primary major adverse cardiac events (MACE) end point (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 13% and 24%, respectively...
July 2017: Diabetes Care
https://www.readbyqxmd.com/read/28615237/erratum-combination-therapy-with-exenatide-plus-pioglitazone-versus-basal-bolus-insulin-in-patients-with-poorly-controlled-type-2-diabetes-on-sulfonylurea-plus-metformin-the-qatar-study-diabetes-care-2017-40-325-331
#16
Muhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, John Adams, Curtis Triplitt, Ralph A DeFronzo, Mahmoud Zirie, Amin Jayyousi
No abstract text is available yet for this article.
August 2017: Diabetes Care
https://www.readbyqxmd.com/read/28611037/inhibition-of-renal-sodium-glucose-cotransport-with-empagliflozin-lowers-fasting-plasma-glucose-and-improves-%C3%AE-cell-function-in-subjects-with-impaired-fasting-glucose
#17
Muhammad Abdul-Ghani, Hussein Al Jobori, Giuseppe Daniele, John Adams, Eugenio Cersosimo, Curtis Triplitt, Ralph A DeFronzo
The objective of this study was to examine the effect of renal sodium-glucose cotransporter inhibition with empagliflozin on the fasting plasma glucose (FPG) concentration and β-cell function in subjects with impaired fasting glucose (IFG). Eight subjects with normal fasting glucose (NFG) and eight subjects with IFG received empagliflozin (25 mg/day) for 2 weeks. FPG concentration and β-cell function was measured with a nine-step hyperglycemic clamp before and 48 h and 14 days after the start of empagliflozin...
September 2017: Diabetes
https://www.readbyqxmd.com/read/28544369/american-association-of-clinical-endocrinologists-2017
#18
Abigail E Dove, Payal H Marathe, Helen X Gao, Kelly L Close
Abigail E. Dove, Payal H. Marathe, Helen X. Gao, and Kelly L. Close are of Close Concerns (http://www.closeconcerns.com), a healthcare information company focused exclusively on diabetes and obesity care. Close Concerns publishes Closer Look, a periodical that brings together news and insights in these areas. Each month, the Journal of Diabetes includes this News feature, in which Dove, Marathe, Gao, and Close review the latest developments relevant to researchers and clinicians.
September 2017: Journal of Diabetes
https://www.readbyqxmd.com/read/28515064/genetics-of-serum-carotenoid-concentrations-and-their-correlation-with-obesity-related-traits-in-mexican-american-children
#19
Vidya S Farook, Lavanya Reddivari, Srinivas Mummidi, Sobha Puppala, Rector Arya, Juan Carlos Lopez-Alvarenga, Sharon P Fowler, Geetha Chittoor, Roy G Resendez, Birunda Mohan Kumar, Anthony G Comuzzie, Joanne E Curran, Donna M Lehman, Christopher P Jenkinson, Jane L Lynch, Ralph A DeFronzo, John Blangero, Daniel E Hale, Ravindranath Duggirala, Jairam Kp Vanamala
Background: Dietary intake of phytonutrients present in fruits and vegetables, such as carotenoids, is associated with a lower risk of obesity and related traits, but the impact of genetic variation on these associations is poorly understood, especially in children.Objective: We estimated common genetic influences on serum carotenoid concentrations and obesity-related traits in Mexican American (MA) children.Design: Obesity-related data were obtained from 670 nondiabetic MA children, aged 6-17 y. Serum α- and β-carotenoid concentrations were measured in ∼570 (α-carotene in 565 and β-carotene in 572) of these children with the use of an ultraperformance liquid chromatography-photodiode array...
July 2017: American Journal of Clinical Nutrition
https://www.readbyqxmd.com/read/28477418/sodium-glucose-co-transporter-sglt-and-glucose-transporter-glut-expression-in-the-kidney-of-type-2-diabetic-subjects
#20
Luke Norton, Christopher E Shannon, Marcel Fourcaudot, Cheng Hu, Niansong Wang, Wei Ren, Jun Song, Muhammad Abdul-Ghani, Ralph A DeFronzo, Jimmy Ren, Weiping Jia
The sodium-glucose co-transporters (SGLTs) are responsible for the tubular reabsorption of filtered glucose from the kidney into the bloodstream. The inhibition of SGLT2-mediated glucose reabsorption is a novel and highly effective strategy to alleviate hyperglycaemia in patients with type 2 diabetes mellitus (T2DM). However, the effectiveness of SGLT2 inhibitor therapy is diminished due, in part, to a compensatory increase in the maximum reabsorptive capacity (Tm) for glucose in patients with T2DM. We hypothesized that this increase in Tm could be explained by an increase in the tubular expression of SGLT and glucose transporters (GLUT) in these patients...
September 2017: Diabetes, Obesity & Metabolism
keyword
keyword
50470
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"